Paul D Morrison

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi Schizophrenia
    Paul D Morrison
    Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
    Curr Biol 15:R980-4. 2005
  2. ncbi Cannabis, the mind and society: the hash realities
    Robin M Murray
    Institute of Psychiatry, Psychological Medicine, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK
    Nat Rev Neurosci 8:885-95. 2007
  3. ncbi Cannabis use and psychiatric and cogitive disorders: the chicken or the egg?
    Marta Di Forti
    Department of Psychological Medicine, Institute of Psychiatry, London, UK
    Curr Opin Psychiatry 20:228-34. 2007
  4. ncbi Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study
    Emma Barkus
    Institute of Psychiatry, Kings College London, London, UK
    J Psychopharmacol 25:1462-8. 2011
  5. ncbi Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation
    P D Morrison
    Kings College London, The Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
    Hum Psychopharmacol 26:77-80. 2011
  6. ncbi Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms
    Paul D Morrison
    The Biomedical Research Centre, Institute of Psychiatry, King s College London, Denmark Hill, UK
    Neuropsychopharmacology 36:827-36. 2011
  7. ncbi From real-world events to psychosis: the emerging neuropharmacology of delusions
    Paul D Morrison
    Institute of Psychiatry, King s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
    Schizophr Bull 35:668-74. 2009
  8. ncbi The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning
    P D Morrison
    Institute of Psychiatry, The Biomedical Research Centre, King s College London, UK
    Psychol Med 39:1607-16. 2009
  9. ncbi What is the mechanism whereby cannabis use increases risk of psychosis?
    Sonija Luzi
    Institute of Psychiatry, Division of Psychological Medicine, Denmark Hill, London, SE5 8AF, UK
    Neurotox Res 14:105-12. 2008
  10. ncbi Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
    Amir Englund
    The Biomedical Research Centre, Institute of Psychiatry, King s College London, UK
    J Psychopharmacol 27:19-27. 2013

Detail Information

Publications15

  1. ncbi Schizophrenia
    Paul D Morrison
    Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
    Curr Biol 15:R980-4. 2005
  2. ncbi Cannabis, the mind and society: the hash realities
    Robin M Murray
    Institute of Psychiatry, Psychological Medicine, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK
    Nat Rev Neurosci 8:885-95. 2007
    ....
  3. ncbi Cannabis use and psychiatric and cogitive disorders: the chicken or the egg?
    Marta Di Forti
    Department of Psychological Medicine, Institute of Psychiatry, London, UK
    Curr Opin Psychiatry 20:228-34. 2007
    ..Cannabis is the world's most commonly used illicit drug. In this review, we consider the recent literature on the effects of cannabis on mental health and on cognition...
  4. ncbi Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study
    Emma Barkus
    Institute of Psychiatry, Kings College London, London, UK
    J Psychopharmacol 25:1462-8. 2011
    ..THC did not lead to a significant increase in DA release even though the dose was sufficient for participants to have psychotic symptoms. These findings do not support a central role for striatal DA in THC-elicited psychosis...
  5. ncbi Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation
    P D Morrison
    Kings College London, The Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
    Hum Psychopharmacol 26:77-80. 2011
    ..It is unknown if cannabis recreates the negative symptoms of schizophrenia...
  6. ncbi Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms
    Paul D Morrison
    The Biomedical Research Centre, Institute of Psychiatry, King s College London, Denmark Hill, UK
    Neuropsychopharmacology 36:827-36. 2011
    ..The results reveal that the pro-psychotic effects of THC might be related to impaired network dynamics with impaired communication between the right and left frontal lobes...
  7. ncbi From real-world events to psychosis: the emerging neuropharmacology of delusions
    Paul D Morrison
    Institute of Psychiatry, King s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
    Schizophr Bull 35:668-74. 2009
    ..Here, we discuss how the 3 modulators regulate learning within the striatum and how their dysfunction may lead to delusional thinking...
  8. ncbi The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning
    P D Morrison
    Institute of Psychiatry, The Biomedical Research Centre, King s College London, UK
    Psychol Med 39:1607-16. 2009
    ..In a study of intravenous (i.v.) synthetic THC in healthy humans, we aimed to study the relationship of the psychotic symptoms induced by THC to the consequent anxiety and neuropsychological impairment...
  9. ncbi What is the mechanism whereby cannabis use increases risk of psychosis?
    Sonija Luzi
    Institute of Psychiatry, Division of Psychological Medicine, Denmark Hill, London, SE5 8AF, UK
    Neurotox Res 14:105-12. 2008
    ..This paper starts to consider the neurochemical mechanisms whereby cannabis use increases the risk of psychosis...
  10. ncbi Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
    Amir Englund
    The Biomedical Research Centre, Institute of Psychiatry, King s College London, UK
    J Psychopharmacol 27:19-27. 2013
    ..6 ± 18.9%) compared with the CBD group (-0.4% ± 9.7 %) (t=2.39, p<0.05). These findings support the idea that high-THC/low-CBD cannabis products are associated with increased risks for mental health...
  11. ncbi Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology
    Sagnik Bhattacharyya
    Section of Neuroimaging, Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, King s College London, London, UK
    Neuropsychopharmacology 35:764-74. 2010
    ..Delta-9-THC and CBD can have opposite effects on regional brain function, which may underlie their different symptomatic and behavioral effects, and CBD's ability to block the psychotogenic effects of Delta-9-THC...
  12. ncbi Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review
    James M Stone
    King s College London Institute of Psychiatry, London, UK
    J Psychopharmacol 21:440-52. 2007
    ..We consider the case for glutamatergic excitotoxicity as a key process in the development and progression of schizophrenia, and suggest ways in which glutamate and dopamine dysregulation may interact in the condition...
  13. ncbi Cannabis in the arm: what can we learn from intravenous cannabinoid studies?
    Amir Englund
    King s College London, Institute of Psychiatry, Denmark Hill, London SE5 8AF
    Curr Pharm Des 18:4906-14. 2012
    ..Here in a critical review, we appraise the major findings from recent intravenous cannabinoid studies in humans and trace the historical roots of this work back to the 1970's...
  14. ncbi Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light
    Alessandra Paparelli
    Division of Psychological Medicine, Institute of Psychiatry, King s College London London, UK
    Front Behav Neurosci 5:1. 2011
    ..In this review we examine the main hypotheses resulting from the link observed between the most common psychotomimetic drugs (lysergic acid diethylamide, amphetamines, cannabis, phencyclidine) and schizophrenia...
  15. ncbi Schizophrenia: more evidence for less glutamate
    Paul D Morrison
    Institute of Psychiatry, De Crespigny Hill, London SE5 8AF, UK
    Expert Rev Neurother 7:29-31. 2007
    ..These findings underscore the importance of NMDA receptors in schizophrenia and support therapeutic strategies aimed at boosting glutamate transmission...